41 Years of Experience
Affiliated with a Castle Connolly Top Hospital
Who is Dr. Valantine, Cardiologist in Stanford, CA?
Dr. Hannah Valantine, MD is a Cardiologist, who primarily practices in Stanford, CA with 1 additional practice location. She has been practicing for over 41 years. Dr. Valantine graduated from St. George's University of London. Dr. Valantine is fluent in English and French, and is currently seeing new patients. Dr. Valantine’s practice accepts Medicaid, Medicare and other major insurance plans. To book an appointment or to confirm insurance options, please call Dr. Valantine’s office at (650) 497-8000.
Where did Dr. Valantine go to medical school and complete their residency?
Medical School: University College, University of London,London, United Kingdom | St. George's University of London
What languages does Dr. Valantine speak?
Dr. Valantine and their clinical team can communicate with patients in the following languages:
English
French
What conditions does a Cardiologist like Dr. Valantine typically treat?
As a Cardiologist, Dr. Valantine diagnoses, treats, and manages a wide range of conditions. This condition information is derived from anonymized insurance claims and highlights the medical conditions most commonly treated by Dr. Valantine. It provides insight into the doctor’s areas of experience and expertise based on real-world patient encounters from the past two years, updated quarterly. Learn more about our claims-based healthcare methodology here.
Also known as:
- Other Long-Term Drug Therapy
- Chronic medication use
- Ongoing drug treatment
- Extended drug therapy
ICD-10 Codes:
- Z79899: Other long term (current) drug therapy
What procedures does a Cardiologist like Dr. Valantine typically perform?
As a Cardiologist, procedures performed by Dr. Hannah Valantine may include:
- Absent Pulmonary Valve Repair
- Anomalous Coronary Artery Angiography
- Anticoagulation Management
- Aortic Stenosis Repair
- Aortic Valve Repair / Replacement
- Aortopulmonary Window Repair
- Arterial Doppler
- Balloon Septostomy
Please contact Dr. Valantine's office directly to confirm care for your specific procedure, for more information, or to schedule a consultation.
Does Dr. Valantine accept my insurance?
Dr. Valantine accepts most major insurance plans. Important: Please call our office at (650) 497-8000 before your appointment to verify that your specific plan and network are accepted.
What insurance plans does Dr. Valantine accept in Stanford, CA?
Dr. Valantine in Stanford, CA accepts plans from many carriers. While this list is updated regularly, it is not a guarantee of coverage.
Top Insurances
All Other Third Party
AllCare Health
Blue Shield of California
Centene Corporation
CVS Health (formerly Aetna)
Medicaid
Medicare
State of California
UnitedHealth Group
Unknown
View All Insurances
Where is Dr. Valantine's office located?
Recognitions
Publications
Transdiscipliry translatiol science and the case of preterm birth
, 2013
Proliferation sigl inhibitors and post-transplant maligncies in heart transplantation
, 2011
Decisions, Decisions: How Program Diversity Influences Residency Program Choice
, 2011
Impact of Donor-Transmitted Atherosclerosis on Early Cardiac Allograft Vasculopathy
, 2011
Identification and Classification of Acute Cardiac Rejection by Intragraft Transcriptiol Profiling
, 2011
Universal noninvasive detection of solid organ transplant rejection
, 2011
Academic Couples: Implications for Medical School Faculty Recruitment and Retention
, 2011
Differentially Expressed R from Public Microarray Data Identifies Serum Protein Biomarkers
, 2010
Gene-Expression Profiling for Rejection Surveillance after Cardiac Transplantation
, 2010
Changing trends in infectious disease in heart transplantation
, 2010
Right Ventricular Dysfunction Predicts Poor Outcome Following Hemodymically Compromising Rejection
, 2009
New developments in immunosuppressive therapy for heart transplantation
, 2009
Twenty-year survivors of heart transplantation at Stanford University
, 2008
Effect of rapamycin therapy on corory artery physiology early after cardiac transplantation
, 2008
Asymmetric dimethylarginine and cardiac allograft vasculopathy progression: Modulation by sirolimus
, 2008
Determints of lumen loss between years 1 and 2 after cardiac transplantation
, 2007
Outcome in cardiac recipients of donor hearts with increased left ventricular wall thickness
, 2007
Molecular testing for long-term rejection surveillance in heart transplant recipients
, 2007
Cytomegalovirus-associated allograft rejection in heart transplant patients
, 2007
Is there a role for proliferation sigl
, 2007
Frequent occult infection with cytomegalovirus
, 2007
Changes in corory atomy and physiology after heart transplantation
, 2007
Interplay between systemic inflammation
, 2007
Changes in corory arterial dimensions early after cardiac transplantation
, 2007
Pulmory nocardiosis in a heart transplant patient: Case report and review of the literature
, 2007
Peripheral blood leukocyte counts in cytomegalovirus infected heart transplant patients
, 2006
Giant corory aneurysms in heart transplantation
, 2006
T-cell immunity to subclinical cytomegalovirus infection reduces cardiac allograft disease
, 2006
Acute rejection and cardiac allograft vascular disease is reduced by suppression of subclinical
, 2006
Discordant changes in epicardial and microvascular corory physiology after cardiac transplantation
, 2006
Wound healing complications with de novo sirolimus versus mycophenolate mofetil
, 2006
Validation of a screening protocol for identifying low-risk c
, 2006
Recurrence of iron deposition in the cardiac allograft in a patient with non-HFE hemochromatosis
, 2006
Use of the implantable cardioverter-defibrillator in long
, 2005
Induction therapy for pediatric and adult heart transplantation
, 2005
From clinical trials to clinical practice
, 2005
Certican (Everolimus) in heart transplantation
Prevention of cardiac allograft vasculopathy with Certican((R)) (everolimus)
, 2005
Cardiac allograft vasculopathy after heart transplantation: Risk factors and magement
, 2004
Glucose intolerance, as reflected by hemoglobin A(1c) level
, 2004
Cytomegalovirus infection impairs the nitric oxide synthase pathway
, 2004
The role of viruses in cardiac allograft vasculopathy
, 2004
Alysis of survivors more than 10 years after heart transplantation in the cyclosporine era
, 2004
Longer-term risks associated with 10
, 2003
Cardiac allograft vasculopathy: Central role of endothelial injury leading to transplant atheroma
, 2003
Post-operative conversion from cyclosporine to tacrolimus in heart transplantation
, 2003
Preferential involvement of larger vessels in a rat model of diabetes induced graft vasculopathy
, 2002
Conversion of cyclosporine to tacrolimus for refractory or persistent myocardial rejection
, 2002
Mycophenolic acid concentrations in long-term heart transplant patients
, 2002
Reversal of diabetes-induced rat graft transplant corory artery disease by metformin
, 2002
Detection of early atherosclerosis with radiolabeled monocyte chemoattractant protein
, 2001
Impact of cytomegalovirus hyperimmune globulin on outcome after cardiothoracic transplantation
, 2001
Transplant corory artery disease - A novel model independent of cellular alloimmune response
, 2001
Detection and treatment of corory artery disease in liver transplant candidates
, 2001
Mild hyperhomocysteinemia is not associated with cardiac allograft corory disease
, 2001
Severe tricuspid regurgitation after heart transplantation
, 2001
Metabolic abnormalities characteristic of dysmetabolic syndrome predict the development of
, 2001
Impact of type 1 diabetes on microvascular vs. macrovascular involvement with TXCAD
, 2001
Neoral use in the cardiac transplant recipient
, 2000
Impact of prophylactic immediate posttransplant ganciclovir on development of transplant
, 1999
Role of CMV in transplant corory artery disease and survival after heart transplantation.
, 1999
Diabetes and dyslipidemia - A new model for transplant corory artery disease
, 1998
Scedosporium apiospermum (Pseudallescheria boydii) infection in a heart transplant recipient
, 1998
Importance of decreased heart rate in predicting transplant corory artery disease
, 1997
Individualizing immunosuppression for heart transplantation: Strategies for the next decade
, 1997
Heart transplantation in patients over 54 years of age - Mortality, morbidity and quality of life
, 1997
Methotrexate or total lymphoid radiation
, 1997
Significant reduction in the number of fungal infections after lung-, heart-lung
, 1997
Volume-mediated pulmory responses in liver transplant candidates
, 1996
Early Doppler echocardiographic dysfunction is associated with an increased mortality after
, 1996
Induction of nitric oxide synthase
, 1996
Corory artery intimal thickening in the transplanted heart
, 1996
Prophylactic ganciclovir treatment reduces fungal as well as cytomegalovirus infections after heart
, 1995
The relationship of granzyme A and perforin expression to cardiac allograft rejection
, 1995
PROGNOSTIC IMPORTANCE OF INTIMAL THICKNESS AS MEASURED BY INTRACORORY ULTRASOUND AFTER CARDIAC
, 1995
Incidence and progression of transplant corory artery disease over 1 year
, 1995
Role of lipids in allograft vascular disease
, 1995
MAGNETIC-RESONCE IMAGING
, 1995
PREVENTION AND TREATMENT OF CYTOMEGALOVIRUS DISEASE IN THORACIC ORGAN TRANSPLANT PATIENTS
, 1995
CORRELATION OF DONOR CHARACTERISTICS WITH TRANSPLANT CORORY
, 1995
CLINICAL OUTCOME OF INTERVAL CADAVERIC REL-TRANSPLANTATION IN CARDIAC ALLOGRAFT RECIPIENTS
, 1995
CARDIAC ALLOGRAFT VASCULAR-DISEASE
, 1995
Distribution and morphologic features of corory artery disease in cardiac allografts
, 1995
INCIDENCE AND SEVERITY OF TRANSPLANT CORORY
, 1995
FEASIBILITY OF SERIAL INTRACORORY ULTRASOUND IMAGING FOR ASSESSMENT OF PROGRESSION OF INTIMAL
, 1994
IMPACT OF CYCLOSPORINE DOSE ON LONG-TERM OUTCOME AFTER HEART-TRANSPLANTATION
, 1994
CYTOKINES AS POTENTIAL MEDIATORS OF ACUTE ALLOGRAFT DIASTOLIC DYSFUNCTION IN CYCLOSPORINE
, 1994
Cytokine gene expression in human cardiac allograft recipients.
, 1994
CARDIAC TRANSPLANTATION - THE STANFORD EXPERIENCE IN THE CYCLOSPORINE ERA
, 1994
EXERCISE ECHOCARDIOGRAPHY IN HEAT TRANSPLANT RECIPIENTS
, 1994
METABOLIC RISK-FACTORS FOR ATHEROSCLEROSIS IN HEART-TRANSPLANT RECIPIENTS
, 1994
RECOVERY OF THE RIGHT VENTRICLE AFTER SINGLE-LUNG TRANSPLANTATION IN PULMORY-HYPERTENSION
, 1994
INFLUENCE OF GRAFT-REJECTION ON INCIDENCE OF ACCELERATED GRAFT CORORY
, 1993
INTRACORORY ULTRASOUND IMAGING IN HEART-TRANSPLANT RECIPIENTS - THE STANFORD EXPERIENCE
, 1992
INTRACORORY ULTRASOUND IN CARDIAC TRANSPLANT RECIPIENTS
, 1992
COST CONTAINMENT - COADMINISTRATION OF DILTIAZEM WITH CYCLOSPORINE AFTER HEART-TRANSPLANTATION
, 1992
NITROGLYCERIN-INDUCED CORORY VASODILATION IN CARDIAC TRANSPLANT RECIPIENTS
, 1992
SENSITIVITY AND SPECIFICITY OF DIASTOLIC INDEXES FOR REJECTION SURVEILLANCE
, 1991
FREQUENCY AND MECHANISM OF BRADYCARDIA IN CARDIAC TRANSPLANT RECIPIENTS AND NEED FOR PACEMAKERS
, 1991
CHANGES IN CARDIAC MORPHOLOGY AND FUNCTION FOLLOWING SINGLE-LUNG TRANSPLANTATION
, 1991
LEFT-VENTRICULAR DIASTOLIC FUNCTION
, 1990
Variability of Doppler echocardiographic indexes of left ventricular filling
, 1990
SERIAL MEASUREMENT OF INTEGRATED ULTRASONIC BACKSCATTER IN HUMAN CARDIAC ALLOGRAFTS FOR THE
, 1990
CARDIAC TRANSPLANTATION IN PATIENTS WITH PREEXISTING NEOPLASTIC DISEASES
, 1990
Long-term magement and results in heart transplant recipients.
, 1990
Prevalence of accelerated corory artery disease
, 1989
RECURRENCE OF AMYLOID IN A CARDIAC ALLOGRAFT 4 MONTHS AFTER TRANSPLANTATION
, 1989
FREQUENCY OF FAMILIAL TURE OF DILATED CARDIOMYOPATHY AND USEFULNESS OF CARDIAC TRANSPLANTATION IN
, 1989
INCREASING PERICARDIAL-EFFUSION IN CARDIAC TRANSPLANT RECIPIENTS
, 1989
INCREASED BETA-RECEPTOR DENSITY AND IMPROVED HEMODYMIC
, 1989
A HEMODYMIC AND DOPPLER ECHOCARDIOGRAPHIC STUDY OF VENTRICULAR-FUNCTION IN LONG
, 1989
CARDIAC TRANSPLANTATION
, 1989
Changes in Doppler echocardiographic indexes of left ventricular function
, 1987
Cardiac sarcoidosis: response to steroids and transplantation.
, 1987
What is Dr. Valantine's NPI number?An National Provider Identifier (NPI) is a unique ID number that identifies doctors and healthcare providers nationwide.
Dr. Valantine's National Provider Identifier (NPI) number is 1063548212.
What common questions do patients ask about Dr. Valantine?
Here are answers to patients Frequently Asked Questions (FAQ’s) about Dr. Valantine
What is Dr. Hannah Valantine's specialty?
Dr. Valantine is a Cardiologist near Stanford, CA.
What does a Cardiologist do?
An internist specializing in cardiovascular diseases focuses on the diagnosis and management of complex heart and blood vessel conditions, including heart attacks and life-threatening arrhythmias.
Is this Dr. Hannah Valantine affiliated with a ranked Castle Connolly Top Hospital?
Yes, Dr. Valantine is affiliated with Stanford Health Care - Stanford Hospital which is a Castle Connolly Top Hospital. Castle Connolly Top Hospitals are healthcare institutions recognized for their excellence in specific medical procedures and overall patient care. They are identified through a rigorous peer nomination process, evaluating factors like patient outcomes, quality of care, and expertise. The list recognizes hospitals that excel in 20 or more specific medical procedures, representing the top 25% nationwide. Castle Connolly Top Hospitals
When to see a Cardiologist?: Guides for symptoms, conditions, and treatments
Understand your symptoms and know when it’s time to see a Cardiologist. Explore insights from trusted medical experts on EverydayHealth.com, where you'll find the most relevant content and helpful condition guides for up-to date information about symptoms, causes, diagnosis, treatment and more. See all our health guides to find trusted information on medical conditions from our experts at Everyday Health.
Is Hannah Valantine accepting new patients in Stanford, CA?
Yes, Dr. Hannah Valantine is accepting new patients at this time.
Does Dr. Hannah Valantine offer online booking?
Please contact Dr. Valantine's office at (650) 497-8000 for information about online booking, telehealth, or to schedule an appointment.
How can I make an appointment with Hannah Valantine?
Please contact Dr. Valantine's office at (650) 497-8000 for information regarding telehealth appointment availability or for scheduling assistance.
Other Cardiologist Near Stanford, CA
Cardiologist
Accepting patientsCardiologist
Accepting patientsCardiologist
Accepting patients